This study is currently not recruiting participants.

RTOG-0415; A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer

Study on Radiation Therapy for Intermediate-Stage Prostate Cancer

Not Recruiting
18 years - 100 years
Male
Phase N/A

Brief description of study.

This randomized phase III trial is studying several different radiation therapy regimens to compare how well they work in treating patients with stage II prostate cancer.

Detailed description of study

The purpose of this study is to compare the disease-free survival (DFS) of patients with favorable-risk stage II prostate cancer treated with hypofractionated vs conventionally fractionated three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Prostate Cancer
  • Age: 18 years - 100 years
  • Gender: Male

This study investigates different radiation therapy regimens for treating patients with stage II prostate cancer. Prostate cancer is a disease where cancer cells form in the tissues of the prostate, a gland in the male reproductive system. The study aims to compare two types of radiation treatments: hypofractionated and conventionally fractionated radiotherapy, which are methods of delivering radiation in different doses and schedules.

Participants will receive one of the two types of radiation therapy: three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT). These are advanced techniques that use computer technology to target cancer cells more precisely, potentially reducing damage to surrounding healthy tissue.

  • Who can participate: Men aged 18 and older who have been diagnosed with intermediate-stage prostate cancer and meet other specific health criteria are eligible to participate.
  • Study details: Participants will be randomly assigned to receive either hypofractionated or conventionally fractionated radiotherapy. All participants will receive active treatment.
Updated on 19 Feb 2024. Study ID: 1010002081 (1403447865)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team